Siegfried (SIX: SFZN), a global contract development and manufacturing organization (CDMO) for the pharmaceutical industry, announced on April 24, 2026, that it has obtained all necessary antitrust clearances and satisfied all closing conditions for its acquisition of three drug substance manufacturing sites. The transaction, which involves facilities located in the United States and Australia, is scheduled to officially close on May 1, 2026. This regulatory milestone allows the company to move forward with the integration of assets previously held by an affiliate of SK Capital Partners.
The acquisition includes three small-molecule drug substance sites that expand Siegfried’s global manufacturing footprint. The facilities are Noramco, a large-scale commercial manufacturing site in Wilmington, Delaware; Purisys, a clinical-stage active pharmaceutical ingredient (API) development and manufacturing facility in Athens, Georgia; and Extractas Bioscience, a producer of purified botanical products based in Westbury, Tasmania. Approximately 400 employees from these three locations will join Siegfried’s global network upon the completion of the transaction.
Following the receipt of antitrust clearance, Siegfried updated its financial guidance for the 2026 fiscal year to reflect the impact of the new assets. The company expects the acquired sites to contribute approximately USD 100 million in net sales for the remainder of 2026, with an annualized revenue contribution estimated at approximately USD 155 million. The transaction is projected to operate at a core EBITDA margin that is at or above the current group average.
As a result of the deal, Siegfried has revised its 2026 growth outlook upward. The company now anticipates net sales growth in the high-single-digit percentage range in local currencies for its Drug Substances cluster, a significant increase from the previously guided low-single-digit growth. Consequently, the consolidated group outlook for net sales growth has also been raised to the high-single-digit range. The target for the core EBITDA margin remains unchanged at over 23%.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, stated that the milestone is a key component of the company’s EVOLVE+ strategy. He noted that the additional manufacturing capacity in the United States and the complementary capabilities in early-phase development and extraction expertise would enhance the company’s ability to support customers from initial development through to commercial production. Specifically, Siegfried plans to optimize its controlled substance capacity by integrating the Wilmington site with its existing facility in Pennsville, New Jersey.
The acquisition strengthens Siegfried’s presence in the United States, the world’s largest pharmaceutical market, and expands its technological reach in the exclusive synthesis business. The company confirmed its positive mid-term outlook, targeting profitable growth above the market average, excluding the impact of future mergers and acquisitions.